In this video, Motley Fool health-care analyst David Williamson takes a closer look at what has propelled Aegerion Pharmaceuticals (NASDAQ: AEGR) to new heights and what it means for its potential competitor Isis Pharmaceuticals (ISIS +2.65%). He also discusses Merck's (MRK +3.27%) latest stumble, a failed study that may get an approved drug pulled from the market.
The stock is hitting new 52-week highs post FDA approval.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid